Fagron N.V.

FAGR

BE0003874915

Pharmaceuticals

Real-time Euronext Bruxelles Other stock markets 06:03:39 2024-05-16 am EDT			5-day change	1st Jan Change
18.9 ^EUR	+0.11%		+0.64%	+13.79%

Apr. 11	Transcript : Fagron NV, Q1 2024 Sales/ Trading Statement Call, Apr 11, 2024
Apr. 11	Fagron Reports Revenue Results for the First Quarter Ended 31 March 2024	CI

Fagron NV Terminates Mandate of Ms. Rita Hoke as Member of the Executive Committee

February 07, 2018 at 09:23 am EST

Fagron NV has decided to terminate the mandate of Ms. Rita Hoke as a member of the Executive Committee.

Latest news about Fagron N.V.

Transcript : Fagron NV, Q1 2024 Sales/ Trading Statement Call, Apr 11, 2024	Apr. 11
Fagron Reports Revenue Results for the First Quarter Ended 31 March 2024	Apr. 11	CI
Fagron Provides Earnings Guidance for the Fiscal Year 2024	Apr. 11	CI
Transcript : Fagron NV, 2023 Earnings Call, Feb 15, 2024	Feb. 15
Fagron NV Proposes Dividend	Feb. 15	CI
Fagron NV Provides Earnings Guidance for the Full Year 2024	Feb. 15	CI
Fagron NV Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 14	CI
Fagron NV completed the acquisiton of Parma Produkt Gyógyszergyártó Korlátolt Felelosségu Társaság.	Jan. 22	CI
Fagron Seeks Acquisitions	23-10-12	CI
Fagron Nv Provides Earnings Guidance for 2023	23-10-12	CI
Transcript : Fagron NV, Q3 2023 Sales/ Trading Statement Call, Oct 12, 2023	23-10-12
Fagron NV Reports Revenue Results for the Third Quarter Ended 30 September 2023	23-10-12	CI
Fagron NV signed an agreement to acquire Parma Produkt Gyógyszergyártó Korlátolt Felelosségu Társaság.	23-10-11	CI
Fagron Completes Share Buyback Program	23-09-20	MT
Tranche Update on Fagron NV's Equity Buyback Plan announced on August 3, 2023.	23-09-19	CI
Fagron NV's Equity Buyback announced on August 3, 2023, has closed with 138,372 shares, representing 0.19% for ?2.26 million.	23-09-18	CI
Fagron NV Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-03	CI
Fagron NV Provides Earnings Guidance for the Full Year 2023	23-08-03	CI
Fagron Seeks M&A	23-08-03	CI
Transcript : Fagron NV, H1 2023 Earnings Call, Aug 03, 2023	23-08-03
Fagron NV announces an Equity Buyback for 138,372 shares.	23-08-03	CI
Fagron NV intends to launch an Equity Buyback.	23-08-03	CI
Fagron NV authorizes a Buyback Plan.	23-08-02	CI
Fagron Nv Announces Board Changes	23-05-08	CI
Fagron NV Approves Dividend for the Fiscal Year 2022, Payable on 17 May 2023	23-05-08	CI

Fagron N.V. specializes in the development, marketing and distribution of healthcare products and services intended for healthcare professionals and institutions. The group ensures the sale of pharmaceutical formulas and raw materials, provides third-party pharmaceutical compounding services to pharmacists and hospitals, etc.

Sector

Pharmaceuticals

Calendar

2024-05-20 - Berenberg Manhattan Benelux Conference

More about the company

Income Statement Evolution

More financial data

Ratings for Fagron N.V.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

18.88 EUR

Average target price

21.7 EUR

Spread / Average Target

+14.94%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
FAGRON N.V.	+13.79%	1.5B
ELI LILLY AND COMPANY	+35.01%	709B
NOVO NORDISK A/S	+30.50%	595B
JOHNSON & JOHNSON	-2.60%	367B
MERCK & CO., INC.	+20.83%	334B
ABBVIE INC.	+5.69%	289B
ASTRAZENECA PLC	+14.47%	239B
NOVARTIS AG	+9.41%	211B
ROCHE HOLDING AG	-3.68%	203B
AMGEN INC.	+10.77%	171B

Other Pharmaceuticals

Fagron N.V.

Equities

FAGR

BE0003874915

Pharmaceuticals

Fagron NV Terminates Mandate of Ms. Rita Hoke as Member of the Executive Committee

Latest news about Fagron N.V.

Chart Fagron N.V.

Company Profile

Income Statement Evolution

Ratings for Fagron N.V.

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Other Pharmaceuticals